Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
Among the three primary gynecological malignancies, ovarian cancer has the lowest incidence but the worst prognosis. Because of the poor prognosis of ovarian cancer patients treated with existing treatments, immunotherapy is emerging as a potentially ideal alternative to surgery, chemotherapy, and t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-02-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748231159706 |
| _version_ | 1797838917327650816 |
|---|---|
| author | Xukai Luo MM Yini Shen MM Wu Huang MM Yiting Bao MM Jiahang Mo MM Liangqing Yao MD Lei Yuan MD |
| author_facet | Xukai Luo MM Yini Shen MM Wu Huang MM Yiting Bao MM Jiahang Mo MM Liangqing Yao MD Lei Yuan MD |
| author_sort | Xukai Luo MM |
| collection | DOAJ |
| description | Among the three primary gynecological malignancies, ovarian cancer has the lowest incidence but the worst prognosis. Because of the poor prognosis of ovarian cancer patients treated with existing treatments, immunotherapy is emerging as a potentially ideal alternative to surgery, chemotherapy, and targeted therapy. Among immunotherapies, immune checkpoint inhibitors have been the most thoroughly studied, and many drugs have been successfully used in the clinic. CD47, a novel immune checkpoint, provides insights into ovarian cancer immunotherapy. This review highlights the mechanisms of tumor immune evasion via CD47-mediated inhibition of phagocytosis and provides a comprehensive insight into the progress of the relevant targeted agents in ovarian cancer. |
| first_indexed | 2024-04-09T15:48:39Z |
| format | Article |
| id | doaj.art-86d51004d76d4561833b0a1a56a77b13 |
| institution | Directory Open Access Journal |
| issn | 1526-2359 |
| language | English |
| last_indexed | 2024-04-09T15:48:39Z |
| publishDate | 2023-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj.art-86d51004d76d4561833b0a1a56a77b132023-04-26T13:33:28ZengSAGE PublishingCancer Control1526-23592023-02-013010.1177/10732748231159706Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian CancerXukai Luo MMYini Shen MMWu Huang MMYiting Bao MMJiahang Mo MMLiangqing Yao MDLei Yuan MDAmong the three primary gynecological malignancies, ovarian cancer has the lowest incidence but the worst prognosis. Because of the poor prognosis of ovarian cancer patients treated with existing treatments, immunotherapy is emerging as a potentially ideal alternative to surgery, chemotherapy, and targeted therapy. Among immunotherapies, immune checkpoint inhibitors have been the most thoroughly studied, and many drugs have been successfully used in the clinic. CD47, a novel immune checkpoint, provides insights into ovarian cancer immunotherapy. This review highlights the mechanisms of tumor immune evasion via CD47-mediated inhibition of phagocytosis and provides a comprehensive insight into the progress of the relevant targeted agents in ovarian cancer.https://doi.org/10.1177/10732748231159706 |
| spellingShingle | Xukai Luo MM Yini Shen MM Wu Huang MM Yiting Bao MM Jiahang Mo MM Liangqing Yao MD Lei Yuan MD Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer Cancer Control |
| title | Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer |
| title_full | Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer |
| title_fullStr | Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer |
| title_full_unstemmed | Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer |
| title_short | Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer |
| title_sort | blocking cd47 sirpα signal axis as promising immunotherapy in ovarian cancer |
| url | https://doi.org/10.1177/10732748231159706 |
| work_keys_str_mv | AT xukailuomm blockingcd47sirpasignalaxisaspromisingimmunotherapyinovariancancer AT yinishenmm blockingcd47sirpasignalaxisaspromisingimmunotherapyinovariancancer AT wuhuangmm blockingcd47sirpasignalaxisaspromisingimmunotherapyinovariancancer AT yitingbaomm blockingcd47sirpasignalaxisaspromisingimmunotherapyinovariancancer AT jiahangmomm blockingcd47sirpasignalaxisaspromisingimmunotherapyinovariancancer AT liangqingyaomd blockingcd47sirpasignalaxisaspromisingimmunotherapyinovariancancer AT leiyuanmd blockingcd47sirpasignalaxisaspromisingimmunotherapyinovariancancer |